Greenland Mines Ltd (GRML): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$5.89M
Year ended 2025-12-31
2022-12-31: -$493.0K2023-12-31: -$446.9K2024-12-31: -$2.95M2025-12-31: -$5.89M-$5.89M
2022-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$5.89Mn/m2026-08-14, From 2025-01-01
2024-12-31-$2.95Mn/m2026-08-14, From 2024-01-01
2023-12-31-$446.9Kn/m2025-03-31, From 2023-01-01
2022-12-31-$493.0Kn/a2024-04-17, From 2022-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Greenland Mines Ltd (GRML)2025-12-31-$5.89Mn/m
Dyadic International Inc (DYAI)2025-12-31-$5.70Mn/m
Calidi Biotherapeutics, Inc. (CLDI)2025-12-31-$21.29Mn/m
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31-$6.03Mn/m
Creative Medical Technology Holdings, Inc. (CELZ)2025-12-31-$5.86Mn/m
VivoSim Labs, Inc. (VIVS)2026-03-31-$10.83Mn/m
Silexion Therapeutics Corp (SLXN)2025-12-31-$10.82Mn/m
BioAtla, Inc. (BCAB)2025-12-31-$48.20Mn/m
Intensity Therapeutics, Inc. (INTS)2025-12-31-$9.23Mn/m

Compare GRML, DYAI, CLDI, SCNI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗